Concepedia

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation

Anna C. Calkin, Sara Giunti, Karen Sheehy, Choy-Hoong Chew, Vishal Boolell, Y. S. Rajaram, Mark E. Cooper, Karin Jandeleit‐Dahm

Diabetologia · 2008 · 62 citations · 50 references

DOIFull text

Open access

Concepts

References

50

Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge

William T. Friedewald, Robert I. Levy, Donald S. Fredrickson · Clinical Chemistry · 1972 · 32.5K citations

, , +14

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter et al. · The Lancet · 2003 · 3.8K citations

, , +14

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

, , +9

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

Rory Collins, Jane Armitage, Sarah Parish et al. · The Lancet · 2003 · 2.9K citations

, , +13

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.

Sanjay Rajagopalan, Stephan Kurz, Thomas Münzel et al. · Journal of Clinical Investigation · 1996 · 2.4K citations · Full text

, , +16